AIDS Alert Archives – September 1, 2007
September 1, 2007
View Issues
-
Microbicide researchers are focusing on adherence strategies as setbacks mount
As microbicide research for HIV prevention emerges from its infancy, researchers are learning many hard lessons. -
Expert offers look at issues in microbicide research
Along with adherence, there are a number of challenges HIV researchers face when they work in the field of microbicides. -
Bioethics program prepares Africans to work in HIV care
AU.S.-based bioethics training program has been helping African professionals develop skills that they've taken back to their native countries to work on the behalf of HIV care, prevention, treatment, and other causes. -
FDA Notifications
On August 6, 2007, the FDA approved maraviroc (Selzentry) 150 mg and 300 mg tablets, a CCR5 co-receptor antagonist used in combination with other antiretroviral products for the treatment of adults infected with CCR5-tropic HIV-1. -
Hormonal contraception and HIV risk: A review
esults from past research studies have investigated a possible relationship between hormonal contraceptive use and HIV acquisition, but understanding remained poor due to inconsistent results and shortfalls in study design. -
Lactic Acidosis in Africans Receiving HAART
Nucleoside reverse transcriptase use in persons with HIV infection has been associated with elevated lactic acid levels and lactic acidosis, presumably related to mitochondrial toxicity.